Coronavirus / India's Panacea Biotec partners with US firm to make Covid-19 vaccine

Indian biotech firm Panacea Biotec on Wednesday said it is partnering with US-based Refana to make a potential vaccine for Covid-19. The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year, it said. Panacea's shares jumped 20% on Wednesday after the news.

Deccan Herald : Jun 11, 2020, 03:04 PM
New Delhi: Indian biotech firm Panacea Biotec Ltd said on Wednesday it would partner with U.S.-based Refana Inc to make a potential vaccine for COVID-19.

The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year, Panacea said in a statement to stock exchanges.

Panacea's shares jumped 20% in morning trading on India's National Stock Exchange after the news.